Topic

What is SS-31?

SS-31 (elamipretide) is a small peptide that targets the inner membrane of mitochondria, the parts of the cell that produce energy. Branded elamipretide received accelerated approval in 2025 for Barth syndrome, a rare genetic condition, and that approval does not extend to compounded SS-31, which is different from an FDA-approved product and is not FDA-approved.

These articles cover the science, the trials, side effects, and how SS-31 compares with other mitochondrial peptides. It is prescription-only: a licensed provider reviews every request, and not everyone qualifies.

8 articles on this topic

  1. A woman sits on a stool in a greenhouse beside a watering can

    Forzinity Prescribing Information: Plain English

    Forzinity’s label covers Barth syndrome, a daily injection, and specific safety limits. Here’s what each section means.

    October 8, 2026 · Nadia Okonjo, Health Writer
  2. A woman sits on the grass beside a dog in a meadow holding a dog lead

    SS-31 News: October 2026 Update

    Forzinity's follow-up trial is underway. Fresh mouse and cell studies add research questions, while the label remains limited to Barth syndrome.

    October 8, 2026 · Elena Marsh, Health Writer
  3. A man sits on the grass beside a dog in a meadow holding a dog lead

    Forzinity Approval: One Year Later

    On September 19, 2025, Forzinity became the first treatment for Barth syndrome through accelerated approval. A year later, that narrow decision still rests on a required confirmatory trial.

    September 19, 2026 · Elena Marsh, Health Writer
  4. A woman sits on a bench beside an allotment shed holding gardening gloves

    SS-31 Side Effects: What the Trials Found

    SS-31 most often caused redness, itching, pain, or swelling where it was injected. Most reactions in trials were mild to moderate, but the label also warns about allergic reactions that can become serious.

    September 16, 2026 · Priya Raman, Health Writer
  5. A woman sits in an armchair by a bright windowsill holding a plain ceramic mug

    SS-31 Protocol: What the Trials Actually Used

    There is no single SS-31 cycle supported by human research. The useful evidence is narrower: a labeled plan for one rare disease and several trial schedules that cannot be copied into personal dosing advice.

    September 14, 2026 · Priya Raman, Health Writer
  6. A man sits cross-legged on a bare exercise mat in an empty room, facing the camera, a single potted plant behind him

    SS-31 and MOTS-c: Can You Take Them Together?

    They are both mitochondrial peptides, and that is about where the similarity stops. No published trial has given people both at once — here is what each one has behind it.

    September 12, 2026 · Nadia Okonjo, Health Writer
  7. A woman walks toward the camera on a quiet desert trail in soft morning light

    SS-31 Benefits: What Human Trials Actually Show

    The clearest human evidence for SS-31 is narrow: muscle-strength findings in people with Barth syndrome. Larger trials in other mitochondrial, heart, and eye conditions have produced mixed or negative primary results.

    September 3, 2026 · Elena Marsh, Health Writer
  8. A person walking a small dog along a quiet tree-lined sidewalk at sunrise

    SS-31 Peptide: A Patient's Guide to Elamipretide

    SS-31 and elamipretide are two names for the same four-amino-acid peptide, and its branded injectable form received accelerated approval from the FDA on September 19, 2025 for a single ultra-rare genetic disease.

    August 13, 2026 · Julian Reyes, Health Writer